BIOLINERX Ltd/S (NASDAQ:BLRX) released its earnings results on Thursday. The biotechnology company reported ($0.06) EPS for the quarter, hitting the Zacks’ consensus estimate of ($0.06), Morningstar.com reports.
NASDAQ:BLRX traded down $0.01 during trading hours on Friday, reaching $0.70. The company had a trading volume of 391,694 shares, compared to its average volume of 1,728,884. BIOLINERX Ltd/S has a 1-year low of $0.67 and a 1-year high of $1.84. The company has a market capitalization of $78.77 million, a PE ratio of -2.59 and a beta of 0.87.
A number of equities research analysts recently commented on the company. HC Wainwright set a $4.00 target price on BIOLINERX Ltd/S and gave the stock a “buy” rating in a report on Friday. Oppenheimer set a $3.00 target price on BIOLINERX Ltd/S and gave the stock a “buy” rating in a report on Friday. Zacks Investment Research raised BIOLINERX Ltd/S from a “hold” rating to a “buy” rating and set a $1.00 target price for the company in a report on Thursday, August 16th. Maxim Group reissued a “buy” rating and issued a $2.00 price target on shares of BIOLINERX Ltd/S in a report on Monday, August 13th. Finally, ValuEngine raised BIOLINERX Ltd/S from a “hold” rating to a “buy” rating in a report on Thursday, October 4th. Two research analysts have rated the stock with a hold rating and four have assigned a buy rating to the company’s stock. The stock presently has a consensus rating of “Buy” and a consensus target price of $2.50.
An institutional investor recently bought a new position in BIOLINERX Ltd/S stock. Fosun International Ltd purchased a new stake in BIOLINERX Ltd/S (NASDAQ:BLRX) in the third quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund purchased 1,357,415 shares of the biotechnology company’s stock, valued at approximately $1,412,000. Fosun International Ltd owned 1.27% of BIOLINERX Ltd/S at the end of the most recent quarter. 34.69% of the stock is currently owned by hedge funds and other institutional investors.
COPYRIGHT VIOLATION NOTICE: “BIOLINERX Ltd/S (BLRX) Releases Earnings Results, Hits Expectations” was published by American Banking News and is the sole property of of American Banking News. If you are accessing this piece of content on another publication, it was stolen and reposted in violation of United States and international trademark & copyright laws. The correct version of this piece of content can be read at https://www.americanbankingnews.com/2018/11/10/biolinerx-ltd-s-blrx-releases-earnings-results-hits-expectations.html.
BIOLINERX Ltd/S Company Profile
BioLineRx Ltd., a clinical stage biopharmaceutical development company focused on oncology and immunology. Its development pipeline consists of clinical-stage therapeutic candidates, which include BL-8040, a peptide for the treatment of multiple cancer and hematological indications; AGI-134, an immuno-oncology agent in development for solid tumors; and BL-5010, a customized, proprietary, pen-like applicator for the non-surgical removal of benign skin lesions.
Receive News & Ratings for BIOLINERX Ltd/S Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BIOLINERX Ltd/S and related companies with MarketBeat.com's FREE daily email newsletter.